Merrell Dow Pharmaceuticals

Eli Lilly and Company

Merrell Pharmaceuticals, Inc.

The Dow Chemical Company

Other

Hoechst Marion Roussel

Aventis Pharma Limited

James R. Mccarthy

Michael L. Edwards

Donald P. Matthews

Donald Paul Matthews

James R McCarthy

Anthony John Shuker

Christopher J Rito

Michael Gregory Bell

Charlotte L Barney

Jonathan Edward Green

Jeffrey Paul Whitten

John H McDonald, Iii

Thomas Alan Crowell

Eugene R Wagner

Mark Alan Winter

David Andrew Neel

Prabhakar Kondaji Jadhav

James R Mccarthy

Alan M Warshawsky

Michael L Edwards

Robert J Broersma

Lynn Stacy Gossett

Cynthia Darshini Jesudason

Jeffrey S Sabol

Christine Ann Droste

Alan J Bitonti

Robert J Ardecky

Samuel James Dominianni

Pierre-Yves Michellys

John S Tyhonas

Dawn Alisa Brooks

David A Hay

James R McConnell

Richard E Donaldson

Winton Dennis Jones, Jr

Daryl Lynn Smith

Thomas M Bargar

Konstantinos Gavardinas

Michael Joseph Coghlan

Kevin Robert Fales

William A Van Sickle

Donald A Kaplan

Robert Duquid

Jennifer Ann Vance

Norton P Peet

Philippe Bey

Leonard Larry Winneroski, Jr

James Joseph Droste

Mitchell I Steinberg

James Robert Henry

Yanping Xu

Guoxin Zhu

Timothy A Grese

Scott Eugene Conner

Nathan Bryan Mantlo

Edward C R Smith

Gregory Alan Stephenson

Daniel Ray Mayhugh

Quanrong Shen

Venkatesh Krishnan

Xiaodong Wang

Ashraf Saeed

John K Daniel

Alfred A Renzi

Roger D McDermott

James B McCarthy

Robert Duguid

The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof. 

4-aminobenzonitrile selective androgen receptor modulators

The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly reduced bones mass, osteoporosis, osteopenia, or reduced muscle mass or strength, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof. X-17142. 

Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators

The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction comprising administering to a patient in need thereof an effective amount of a compound of formula (I). 

Tetrahydrocarbazole derivatives useful as androgen receptor modulators

The present invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or inflammation, comprising administering to a patient in thereof an effective amount of a compound of Formula (I). 

Tricyclic steroid hormone nuclear receptor modulators

The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases. 

Sulfonamide derivatives as PPAR modulators

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or inflammation, comprising administering to a patient in thereof an effective amount of a compound of Formula (I). 

The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.

The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.

Modulators of peroxisome proliferator activated receptors (PPAR)

Modulators of peroxisome proliferator activated receptors

The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II:

Selective &bgr;3 adrenergic agonists

The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II: ##STR1##

Selective .beta.-3 adrenergic agonists

Selective .beta..sub.3 adrenergic agonists

The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formula II: ##STR1## The variables in Formula II are defined herein.

Selective .beta.3 adrenergic agonists

Growing community of inventors

Indianapolis, IN, United States of America

Donald Paul Matthews